Integration Of Artificial Intelligence in Nanoparticle-Mediated Drug Delivery: Design, Strategy, Predictive Modeling and Therapeutic Outcomes

K. Hamsika Sri[1], V. Aravinda Krishna[2], A. Kuraloviya [3], Edapalapati Venkata Naga Nithin[4], Shreeya Rajesh Tumme[5], Pragyan Kumar Mishra[6], Amaan Ahmad[7]
[1]MSc, MCC, East Tambaram, Chennai
[2,3]B. Tech, Biotechnology, SRM Institute of Science & Technology, Chennai
[4]M. Tech, Biomedical Data Science, Centre for Life Science, Mahindra University Hyderabad
[5]M. Tech, Medical Devices, Biomedical Engineering, National Institute of Technology, Raipur
[6]B. Pharm, Bansal College of Pharmacy, RGPV University, Bhopal, M.P.
[7]MS.c, Department of Chemistry, Aligarh Muslim University, Aligarh

Abstract—**Nanoparticle-mediated drug delivery systems (NDDS) have emerged as transformative platforms for targeted therapeutics. However, conventional empirical approaches to nanoparticle formulation are resource-intensive and often suboptimal. Artificial intelligence (AI) and machine learning (ML) offer unprecedented opportunities to accelerate and improve the design, optimization, and clinical translation of NDDS. This comprehensive review synthesizes current literature on the integration of AI methodologies including deep learning, graph neural networks, reinforcement learning, and generative adversarial networks into nanoparticle drug delivery research, with emphasis on design strategies, predictive modeling frameworks, and therapeutic outcome improvements A systematic literature search was conducted across PubMed, Scopus, Web of Science, and IEEE Xplore databases (2010–2024). Studies reporting AI-assisted nanoparticle design, formulation optimization, toxicity prediction, drug release modeling, or clinical outcome AI-integrated approaches demonstrated 25–40% improvements in encapsulation efficiency, 33–65% enhancements in tumor targeting specificity, and significant reductions in formulation development timelines (from years to months). Deep learning models achieved >90% accuracy in predicting drug release kinetics, while GNN-based approaches showed superior performance. AI integration into nanoparticle drug delivery represents a paradigm shift from empirical trial-and-error to data-driven precision nanomedicine. Continued development of interpretable AI models, standardized datasets, and regulatory frameworks will be essential for clinical translation.**

Index Terms—**artificial intelligence; nanoparticle; drug delivery; machine learning; deep learning; QSAR; predictive modeling; nanomedicine; therapeutic optimization;**

I. INTRODUCTION

Drug delivery science has undergone remarkable evolution over the past five decades, transitioning from simple oral tablet formulations to sophisticated nanotechnology-based systems capable of site-specific, stimulus-responsive drug release.[1] Nanoparticles (NPs) with dimensions ranging from 1 to 1000 nm offer distinctive advantages over conventional delivery vehicles, including enhanced permeability and retention (EPR) in tumor tissues, protection of labile biomolecules, prolonged systemic circulation, and controlled payload release.[2,3] Liposomes, polymeric nanoparticles, dendrimers, solid lipid nanoparticles (SLNs), inorganic nanoparticles, and more recently exosome-based carriers constitute a diverse toolkit for addressing therapeutic challenges across oncology, infectious disease, neurological disorders, and metabolic conditions.[4,5]

Despite these extraordinary capabilities, nanoparticle formulation development remains a complex, multivariable challenge. The physicochemical properties of nanocarriers including size, surface charge, shape, hydrophobicity, and surface

functionalization collectively govern their biological fate, encompassing protein corona formation, immune recognition, biodistribution, cellular uptake, and intracellular trafficking.[17,29] The sheer dimensionality of the formulation design space has historically limited optimization to time-consuming, resource-intensive empirical approaches that explore only a narrow region of the available parameter landscape.

Artificial intelligence (AI), and particularly its machine learning (ML) and deep learning (DL) subfields, have emerged as transformative technologies capable of navigating high-dimensional biological and chemical data spaces with unprecedented efficiency.[6,7] The convergence of AI with nanomedicine has opened a new frontier in drug delivery science, enabling: (i) rational computational design of nanocarrier architecture; (ii) high-throughput virtual screening of formulation variables; (iii) predictive modeling of in vivo pharmacokinetics; (iv) intelligent identification of patient-specific therapeutic strategies; and (v) accelerated regulatory pathway navigation through digital twin methodologies.[8,46]

This review provides a comprehensive synthesis of the current state of AI integration in nanoparticle-mediated drug delivery, with particular attention to foundational AI methodologies, nanoparticle design strategies, predictive modeling frameworks, therapeutic outcome improvements, and future translational prospects. By bridging computational and experimental perspectives, we aim to provide researchers, clinicians, and pharmaceutical scientists with an authoritative reference for this rapidly evolving interdisciplinary field.[31,48]

II. BACKGROUND AND FOUNDATIONAL CONCEPT

The conceptual foundation of nanoparticle drug delivery can be traced to Langer and Folkman's seminal 1976 work demonstrating sustained polymer-based macromolecule release,[19] followed by the development of liposomal formulations in the 1980s by Gregoriadis and others. The pivotal clinical approvals of Doxil® (liposomal doxorubicin, 1995) and Abraxane® (albumin-bound paclitaxel, 2005) validated the therapeutic utility of nanomedicine and catalyzed intensive research investment. [57,58]

The conceptual emergence of the EPR effect by Maeda et al. provided a mechanistic framework for passive tumor targeting, wherein NPs of 40–200 nm preferentially extravasate and accumulate in tumor interstitium due to leaky tumor vasculature and impaired lymphatic drainage.[22,30] Subsequent decades witnessed the development of active targeting strategies employing surface-conjugated ligands (antibodies, aptamers, peptides, small molecules) for receptor-mediated endocytosis, as well as stimuli-responsive systems exploiting tumor microenvironment characteristics including low pH, elevated glutathione, hypoxia, and overexpressed enzymes.[9,55]

Despite demonstrable preclinical promise, clinical translation rates for nanomedicines remain disappointingly low (estimated <1% of investigated formulations reach patients), primarily attributable to poor predictive power of in vitro and animal models, biological heterogeneity of human tumors, and the absence of rational formulation design tools capable of handling the complexity of the biological-nanomaterial interface.[32,59]

2.1 Fundamentals of Artificial Intelligence and Machine Learning

Artificial intelligence encompasses computational systems capable of performing tasks that conventionally require human intelligence, including pattern recognition, language understanding, and decision-making. In the drug delivery context, the most relevant AI subdivisions include:

Machine Learning (ML): Algorithms that improve performance through experience, including supervised (classification, regression), unsupervised (clustering, dimensionality reduction), and semi-supervised paradigms. Random forests, gradient boosting machines, and support vector machines represent widely applied ML approaches in pharmaceutical sciences. [6,7]

Deep Learning (DL): Multi-layered artificial neural network architectures capable of hierarchical feature extraction from raw data. Convolutional neural networks (CNNs), recurrent neural networks (RNNs), long short-term memory networks (LSTMs), and transformer architectures have demonstrated superior performance in molecular property prediction, image analysis, and sequence modeling tasks relevant to nanomedicine. [34,37]

Graph Neural Networks (GNNs): Specialized architectures that operate on graph-structured data, directly encoding molecular topology, bond connectivity, and atom-level features. GNNs have demonstrated particular utility for predicting molecular properties, designing drug-carrier interactions, and modeling nanomaterial behavior from first principles. [38,39,40]

Generative Models: Including generative adversarial networks (GANs) and variational autoencoders (VAEs), these architectures can generate novel molecular structures or formulation compositions satisfying specified property constraints, enabling de novo nanocarrier design beyond the scope of known chemical space.[36,43]

Reinforcement Learning (RL): Systems that learn optimal decision policies through environmental interaction and reward signals. RL has been applied to molecular design optimization, adaptive drug dosing strategies, and sequential formulation parameter selection in automated experimentation platforms.[8,43]

III. NANOPARTICLE PLATFORM

The diverse landscape of nanoparticle platforms presents distinct design challenges and opportunities for AI integration.[16,17] Each platform is characterized by unique physicochemical parameters governing formulation feasibility, drug loading capacity, release kinetics, and biological performance.

A. Liposomes and Lipid-Based Nanoparticles

Liposomes are spherical vesicles composed of one or more phospholipid bilayers enclosing an aqueous core, enabling simultaneous encapsulation of hydrophilic (aqueous compartment) and hydrophobic (bilayer) drugs. Their biocompatibility, biodegradability, and structural versatility have made them the most clinically advanced nanoparticle platform, with numerous FDA-approved products including Doxil®, DaunoXome®, and Onpattro®.[20,57]

AI approaches applied to liposomal formulation include ML-guided lipid composition screening, where algorithms process physicochemical descriptors of lipid components to predict vesicle stability, encapsulation efficiency, and membrane permeability. Deep learning models trained on large lipid nanoparticle (LNP) datasets have demonstrated the ability to predict transfection efficiency for mRNA delivery with high accuracy, addressing a critical challenge in mRNA therapeutic development.[50,61]

B. Polymeric Nanoparticles

Biodegradable polymeric nanoparticles, particularly those fabricated from poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), and polyethylene glycol (PEG) derivatives, offer precise control over drug release kinetics through polymer molecular weight, copolymer ratio, and crystallinity manipulation.[3,4] Their surface chemistry is highly amenable to functionalization with targeting ligands, imaging agents, and stimuli-responsive moieties.

ML models predicting PLGA nanoparticle size, polydispersity index (PDI), zeta potential, and encapsulation efficiency from formulation parameters (polymer concentration, surfactant type, drug-polymer ratio, organic:aqueous phase ratio) have achieved R^2 values exceeding 0.92 in cross-validated datasets. Bannigan et al. demonstrated that ML-directed screening reduced formulation development cycles from months to weeks while identifying optimal excipient combinations beyond the intuition of expert formulation scientists.[47,52]

C. Dendrimers

Dendrimers are hyperbranched, precisely defined three-dimensional polymeric architectures characterized by a central core, repetitively branched interior, and multiple surface functional groups. Their well-defined molecular architecture confers monodispersity and precisely controllable molecular weight properties highly amenable to computational modeling.[27] Polyamidoamine (PAMAM) dendrimers are the most extensively studied class, with applications ranging from nucleic acid delivery to boron neutron capture therapy (BNCT) agents.

GNN models have been applied to predict dendrimer-drug binding affinities from molecular graph representations, enabling virtual screening of dendrimer generations and surface modifications prior to synthesis. AI has also been instrumental in identifying structural modifications that reduce the well-documented hemolytic and cytotoxic properties of cationic dendrimers.[12,39]

D. Inorganic and Hybrid Nanoparticles

Gold nanoparticles (AuNPs), iron oxide nanoparticles (IONPs), mesoporous silica nanoparticles (MSNs),

and quantum dots offer unique optical, magnetic, and photocatalytic properties enabling multimodal theranostic applications that merge therapy and diagnostics in a single platform.[23,24] Their size and morphology are critical determinants of biodistribution, cellular uptake mechanisms, and therapeutic efficacy.

CNN-based image analysis has been applied to transmission electron microscopy (TEM) images of inorganic NPs for automated size distribution quantification, shape classification, and quality control, dramatically improving throughput compared to manual analysis. AI-guided synthesis optimization has demonstrated utility in controlling AuNP morphology (nanospheres, nanorods, nanostars) for application-specific optical properties

IV. AI DRIVEN NANOPARTICLE DESIGN STRATEGIES

A. Quantitative Structure Activity/Property Relationships (QSAR/QSPR)

QSAR modeling represents one of the most mature computational approaches at the interface of AI and pharmaceutical sciences. By establishing quantitative mathematical relationships between molecular structural descriptors and biological activities or physicochemical properties, QSAR models enable in silico prediction of compound behavior without resource-intensive experimental testing.[53,54]

In the context of nanoparticle delivery, QSAR/QSPR models have been developed for predicting: (i) drug-nanocarrier compatibility and encapsulation efficiency from drug physicochemical descriptors; (ii) membrane permeability coefficients of nanoparticle-associated drugs across biological barriers; (iii) protein corona composition from nanoparticle surface properties; (iv) intracellular trafficking pathways based on NP surface chemistry; and (v) hemolytic potential of cationic carrier systems.[11,10]

The DeepTox platform, developed by Mayr et al., employed deep feedforward neural networks achieving superior performance over traditional QSAR approaches across 12,000+ compounds in the Tox21 toxicity prediction challenge.[12] This represents a pivotal demonstration of DL superiority for high-dimensional toxicity datasets particularly relevant to nanomaterial safety assessment.

B. Molecular Docking and Drug-Nanocarrier Interaction Modeling

AI-enhanced molecular docking algorithms integrate classical docking calculations with ML-trained scoring functions to predict binding geometries and affinities between drug molecules and nanocarrier components (polymer chains, lipid bilayer components, dendrimer surface groups).[64,55] Traditional docking scoring functions suffer from inherent limitations in capturing the flexibility of soft-matter nanocarrier systems; ML-based scoring functions trained on experimental binding data have demonstrated significantly improved predictive accuracy.

Physics-informed neural networks (PINNs) that incorporate fundamental thermodynamic and kinetic constraints alongside learned patterns from experimental data represent a promising frontier for drug-nanocarrier interaction modeling. These hybrid approaches achieve superior generalizability compared to purely data-driven models, particularly important given the relatively limited size of experimental nanoparticle datasets.[64,46]

C. Generative AI for De Novo Nanocarrier Design

Generative AI models represent a paradigm shift from predictive (analyzing existing designs) to prescriptive (creating novel designs) computational approaches. Variational autoencoders (VAEs) encode nanocarrier designs into a continuous latent space from which novel candidates with desired properties can be sampled, while GANs employ adversarial training to generate realistic synthetic formulation data.[36,43]

The application of molecular generative models to lipid nanoparticle design has demonstrated the ability to identify novel ionizable lipid structures with superior mRNA transfection efficiency, exceeding the performance of existing gold-standard formulations (MC3/DLinDMA) when experimentally validated.[61,52] Olivecrona et al. demonstrated that deep RL models could efficiently explore molecular design space, generating compounds with targeted property profiles while maintaining chemical validity.[43]

D. Active Learning and Bayesian Optimization

Bayesian optimization provides a principled probabilistic framework for sequential experimental design, balancing exploration of uncertain regions

with exploitation of known high-performing parameter combinations. In nanoparticle formulation, Bayesian optimization has been applied to efficiently navigate multivariate parameter spaces (polymer concentration, processing conditions, surfactant ratios) to identify optimal formulations within a minimal number of experimental iterations.[8,52]

Reker et al. demonstrated that computationally guided high-throughput design using active learning reduced the number of experiments required to optimize self-assembling drug formulations by 92% compared to traditional design-of-experiments (DoE) approaches.[52] Active learning strategies iteratively select the most informative experiments to maximize model improvement per experimental cycle, a critical advantage in settings where experimental costs are high and training data are scarce.[8]

V. PREDICTIVE MODELING FRAMEWORK

A. Drug Release Kinetics Prediction

Accurate prediction of drug release kinetics from nanoparticle formulations is a central challenge in pharmaceutical product development. Drug release from NDDS involves complex, often nonlinear processes including polymer degradation, diffusion through polymer matrices, dissolution at the particle surface, and swelling-controlled release.[3,4] Classical mathematical models (zero-order, first-order, Higuchi, Korsmeyer-Peppas) provide valuable mechanistic insights but are unable to capture the full complexity of release behavior across diverse formulations and conditions.

LSTM-based recurrent neural networks, which are specifically designed to learn temporal dependencies in sequential data, have demonstrated superior performance for drug release profile prediction compared to conventional ML approaches. Models trained on comprehensive experimental datasets encompassing formulation parameters (polymer type/MW, drug loading, particle size) and environmental conditions (pH, temperature, ionic strength) have achieved mean absolute errors <5% across diverse formulation types.[37,47]

B. Pharmacokinetic and Biodistribution Modeling

Translating in vitro performance to in vivo pharmacokinetics (PK) represents a major bottleneck in nanoparticle drug development. Traditional in vitro-in vivo correlation (IVIVC) approaches applied to NP systems have shown limited predictive power due to the complex interplay of biological barriers, protein adsorption, immune recognition, and tissue-specific uptake mechanisms.[29,31]

AI-powered physiologically based pharmacokinetic (AI-PBPK) models integrate compartmental pharmacokinetic equations with ML-learned tissue-specific distribution parameters, achieving superior predictions of nanoparticle biodistribution in preclinical animal models.[60,31] These models can be trained on large compendiums of published NP biodistribution data, accounting for formulation properties, species differences, and disease state modifications.

Poon et al. analyzed a comprehensive dataset of 1,200+ published nanoparticle in vivo studies, applying ML models to identify the dominant determinants of tumor accumulation efficiency. Their analysis revealed that formulation properties contributed only ~8% of the variance in tumor delivery, while biological and experimental factors dominated outcomes a finding with profound implications for AI model design and the appropriate benchmarks for formulation optimization.[62,30]

C. Toxicity and Safety Prediction

Nanomaterial safety assessment presents unique challenges compared to small-molecule toxicology, as NP toxicity is governed not only by chemical composition but also by physical parameters including size, shape, surface charge, surface area, and agglomeration state.[12,14] Traditional in vitro toxicity assays are time-consuming, and their predictive power for in vivo nanotoxicology is limited.

Nano-QSAR models employing physiochemical NP descriptors as inputs have been developed for predicting cytotoxicity (LC_{50}, IC_{50}), genotoxicity, oxidative stress induction, and inflammatory potential across diverse NP types.[12,54] These models have demonstrated particular value for early screening of novel NP formulations prior to resource-intensive animal studies, potentially reducing both development costs and ethical burden.

High-content screening (HCS) platforms that acquire multiparametric cellular imaging data following NP exposure have been integrated with CNN image analysis to extract quantitative toxicity endpoints from complex morphological cell phenotypes. Blay et al.

demonstrated that CNN-extracted HCS features improved cytotoxicity prediction accuracy by 34% compared to conventional biochemical assays.[45]

Table 1. Summary of AI/ML Methods Applied in Nanoparticle Drug Delivery Research

AI/ML Method	Application in NDDS	Performance Metric	Reference
Random Forest	Nanoparticle size prediction	$R^2 = 0.94$	[47]
Deep Neural Network	Encapsulation efficiency	RMSE = 3.2%	[50]
LSTM Network	Drug release kinetics	MAE = 4.1%	[37]
Graph Neural Network	Molecular property prediction	AUC = 0.91	[39]
Bayesian Optimization	Formulation optimization	92% efficiency gain	[52]
GAN	Novel lipid generation	Validated in vivo	[61]
CNN	TEM image analysis	98.2% accuracy	[33]
Reinforcement Learning	Drug design optimization	Top-10% hits	[43]
Nano-QSAR	Cytotoxicity prediction	$R^2 = 0.87$	[54]
PBPK + ML	Biodistribution prediction	r = 0.89 (tumor)	[31]

NDDS = Nanoparticle Drug Delivery System; RMSE = Root Mean Square Error; MAE = Mean Absolute Error; AUC = Area Under the ROC Curve; GAN = Generative Adversarial Network; CNN = Convolutional Neural Network; PBPK = Physiologically Based Pharmacokinetic Model.

D. Protein Corona Modeling

When nanoparticles enter biological fluids, they rapidly acquire a protein corona a complex adsorbed protein layer that dramatically alters their effective identity, biodistribution, cellular uptake, and immunological response.[29,31] The composition and dynamics of the protein corona are highly sensitive to NP surface chemistry, size, and curvature, as well as the protein composition of the biological milieu.

ML models trained on proteomic datasets from nanoparticle-protein corona characterization experiments have demonstrated the ability to predict corona composition from nanoparticle physicochemical descriptors with reasonable accuracy (R^2 ~0.75–0.85).[28,55] These models are enabling the rational design of stealth NP surfaces that minimize non-specific protein adsorption, extending systemic circulation half-lives.

VI. NANOPARTICLE DESIGN STRATEGIES ENHANCED BY AI

A. Targeted Delivery System Design

Active targeting strategies employ surface-conjugated recognition molecules to mediate specific binding to overexpressed receptors on pathological cells. The design of optimal targeting strategies requires consideration of receptor expression levels, ligand binding affinity and selectivity, steric accessibility on the nanoparticle surface, and the potential for receptor saturation and downregulation.[16,17]

ML-guided ligand selection has been applied to identify optimal peptide sequences, aptamer structures, and small molecule ligands for targeting specific cancer cell surface receptors. Molecular dynamics (MD) simulations combined with ML scoring functions have enabled rapid prediction of ligand-receptor binding affinities across large virtual libraries, dramatically expanding the scope of targetable molecular candidates.[64,46]

AI has also been applied to optimize the surface density and spacing of targeting ligands on NP surfaces critical parameters that govern multivalent binding avidity and nonspecific interactions. Optimal ligand density was found to vary significantly across target receptor types and NP sizes, underscoring the importance of AI-guided multi-parameter optimization.[55,62]

B. Stimuli-Responsive Nanoparticle Design

Stimuli-responsive nanoparticles achieve spatiotemporally controlled drug release by incorporating molecular switches that respond to endogenous tumor microenvironment signals (pH, redox potential, hypoxia, enzymes) or exogenous physical stimuli (light, ultrasound, magnetic fields, temperature).[9,23] The design of these systems requires balancing switch sensitivity with stability in normal tissue environments.

AI has been applied to model the dynamic behavior of stimuli-responsive polymers across pH gradients, identifying optimal polymer compositions for maximum response magnitude and switching kinetics. Reinforcement learning frameworks have been

employed to optimize multistep drug release programs for example, sequential release of sensitizers followed by primary chemotherapeutics for synergistic tumor killing.[9,43]

C. Surface Engineering and PEGylation Optimization

Polyethylene glycol (PEG) surface modification (PEGylation) is the most widely employed strategy for extending NP systemic circulation by creating a hydrophilic steric barrier that inhibits opsonization and macrophage recognition.[25,29] However, the optimal PEG chain length, surface density, and terminal group chemistry are system-specific and interact with other formulation parameters in complex ways.

ML models trained on comprehensive PEGylated NP datasets have identified non-intuitive relationships between PEG molecular weight (2, 5, 10, 20 kDa), grafting density, and in vivo circulation half-life across different NP core materials and sizes. These models have enabled prediction of optimal PEGylation parameters for new formulations without extensive experimental optimization, accelerating the development pipeline.[28,31]

D. Co-loading and Combination Therapy Optimization

Combination therapies employing multiple therapeutic agents with synergistic or complementary mechanisms of action have demonstrated superior clinical outcomes in cancer treatment. Nanoparticle co-loading strategies offer the additional advantage of synchronized co-delivery to the same cancer cells, potentially overcoming heterogeneous tumor drug distribution.[5,16]

AI algorithms have been applied to identify synergistic drug combinations and optimal molar ratios for co-loading in nanoparticles, drawing on comprehensive drug interaction databases such as DrugComb and ALMANAC. ML-guided nanoparticle co-formulation has been shown to identify optimal drug-drug-carrier combinations that maximized synergistic cytotoxicity while minimizing off-target toxicity.[46,60]



Figure 1. Comprehensive AI predictive modeling workflow for nanoparticle drug delivery, from data collection through feature engineering, model selection, validation, prediction, and clinical translation, with active learning feedback loop.

Table 2. Comparative Analysis of Conventional vs. AI-Enhanced Nanoparticle Design Approaches

Design Parameter	Conventional Approach	AI-Enhanced Approach	Key Advantage
Particle size	Empirical titration	ML regression models	15× faster optimization
Encapsulation efficiency	DoE screening	Bayesian optimization	92% fewer experiments
Surface functionalization	Trial-and-error	GNN binding prediction	Rational ligand selection
Drug loading	Experimental screening	QSPR modeling	In silico pre-screening
Release kinetics	Empirical profiling	LSTM neural networks	Multi-condition prediction
Toxicity	In vitro cell assays	CNN/QSAR models	High-throughput screening
Targeting ligand	Literature-based	ML affinity prediction	Expanded candidate space
PEGylation density	Iterative testing	ML optimization	Circulation time maximization

VII. THERAPEUTIC OUTCOME AND CLINICAL IMPLICATION

A. Oncology Applications

Cancer nanomedicine represents the most extensively studied application domain, driven by the oncological unmet need for therapies with improved efficacy and reduced systemic toxicity.[5,16] AI integration has demonstrated measurable improvements across

multiple dimensions of oncological nanoparticle performance. In breast cancer models, AI-optimized liposomal doxorubicin formulations demonstrated 2.8-fold higher tumor accumulation and 40% reduced cardiotoxicity compared to Doxil® in murine xenograft models, through ML-guided optimization of lipid composition, PEGylation density, and targeting antibody conjugation.[57,47] Similar improvements were reported for PLGA-based paclitaxel nanoparticles in lung adenocarcinoma models, where Bayesian optimization identified formulation parameters achieving 91% encapsulation efficiency (versus 68% for conventional approaches).[56,24]

AI-driven identification of patient-specific nanoparticle design parameters based on tumor genomic profiles represents an emerging frontier in precision oncology. By integrating molecular tumor profiling data with NP performance databases, ML models can theoretically predict patient-specific formulation parameters likely to achieve maximum therapeutic benefit.[31,60]

B. Infectious Disease Applications

The COVID-19 pandemic catalyzed an unprecedented acceleration in lipid nanoparticle (LNP) development for nucleic acid delivery, culminating in the emergency authorization of mRNA-LNP vaccines for SARS-CoV-2 within twelve months of viral sequence determination a development timeline ten-fold shorter than conventional vaccine paradigms.[61,20]

AI played a direct role in the rapid optimization of LNP formulations for mRNA encapsulation and intracellular delivery, with ML models trained on high-throughput in vitro screening data enabling rapid identification of ionizable lipid formulations from libraries of >1,000 candidate structures.[61,47] The scalability of AI-guided formulation approaches is particularly evident in infectious disease applications requiring rapid response to emerging pathogens.

C. Central Nervous System Drug Delivery

The blood-brain barrier (BBB) represents one of the most formidable challenges in drug delivery, restricting access of >98% of small molecules and essentially all macromolecular therapeutics to the central nervous system (CNS).[29,9] Nanoparticle-based CNS delivery strategies exploit specific transport mechanisms including receptor-mediated transcytosis, adsorptive-mediated transcytosis, and solid lipid nanoparticle-mediated intracellular pathways.

AI models predicting BBB permeation from nanoparticle physicochemical descriptors have been developed using P-glycoprotein substrate prediction algorithms combined with NP-specific transport datasets. Deep learning models incorporating both drug properties and NP surface chemistry achieved predictive accuracy (AUC = 0.88) significantly superior to traditional in vitro BBB models for CNS delivery prediction.[10,11]

D. Personalized Nanomedicine

The convergence of AI-powered nanoparticle design with patient genomic, transcriptomic, proteomic, and metabolomic ('multi-omic') data enables a vision of truly personalized nanomedicine, wherein nanoparticle formulations are tailored to individual patient disease biology and pharmacogenomic profiles.[31,60]

Computational platforms integrating patient tumor RNA-sequencing data with ML-predicted NP surface functionalization can identify patient-specific optimal targeting ligands based on individual receptor expression profiles. This approach has demonstrated 2–4-fold improvements in tumor cell selectivity in vitro compared to population-average targeting strategies.[46,48]



Figure 2. Comparative therapeutic outcomes between AI-optimized and conventional nanoparticle formulations across key performance metrics, demonstrating consistent improvements conferred by AI-guided design across encapsulation efficiency, drug loading, targeting specificity, bioavailability, cytotoxicity reduction, and therapeutic index.

VIII. CHALLENGES, LIMITATION AND FUTURE PERSPECTIVE

A. Data Quality, Availability and Standardization

The effectiveness of AI models is fundamentally constrained by the quantity and quality of training data. Nanoparticle drug delivery research suffers from significant data challenges including: (i) relatively small experimental datasets by AI standards (hundreds to low thousands of data points); (ii) heterogeneous experimental protocols across laboratories preventing direct dataset pooling; (iii) selective publication bias favoring positive results; (iv) inconsistent characterization reporting standards; and (v) limited sharing of raw experimental data.[47,53]

Community-driven initiatives including the NanoSafety Cluster, the eNanoMapper database, and the Nanomaterial Registry have made progress toward standardized NP characterization data formats, but comprehensive, well-annotated, publicly accessible nanoparticle biological performance datasets remain scarce.[28,32] The development of FAIR (Findable, Accessible, Interoperable, Reusable) data standards specifically for nanomedicine is an urgent research infrastructure priority.

B. Interpretability and Explainability

The inherent 'black box' nature of complex DL models presents significant barriers to regulatory acceptance and scientific understanding. While DL models may achieve superior predictive performance compared to mechanistic models, their internal representations are typically opaque to human interpretation.[41,42] Regulatory agencies including the FDA and EMA increasingly emphasize the importance of explainability for AI-driven pharmaceutical development decisions.

Explainable AI (XAI) approaches including SHAP (SHapley Additive exPlanations) values, LIME (Local Interpretable Model-agnostic Explanations), attention weight visualization in transformer models, and gradient-based saliency maps provide post-hoc interpretability for complex ML models.[42,41] These techniques are increasingly being incorporated into nanoparticle AI pipelines to identify the physicochemical determinants driving predicted performance, generating testable mechanistic hypotheses.

C. Regulatory Framework for AI-Assisted Drug Delivery

The regulatory pathway for AI-assisted nanoparticle drug development remains incompletely defined. While the FDA has issued guidance documents on AI/ML-based software as a medical device, comprehensive guidance specifically addressing AI-assisted formulation development is lacking.[59,31]

Critical regulatory questions include: (i) documentation requirements for AI-guided formulation decisions; (ii) validation standards for predictive models supporting IND applications; (iii) post-market surveillance obligations when AI continues to update models; and (iv) intellectual property considerations for AI-generated formulations.[66,31] Proactive engagement between the nanomedicine research community and regulatory agencies is essential to develop fit-for-purpose regulatory frameworks that enable innovation while ensuring patient safety.

D. Translational Gap: In Silico to In Vivo

Despite impressive in silico performance metrics, AI models for nanoparticle behavior prediction often fail to maintain accuracy when applied to in vivo biological systems.[62,32] The fundamental disconnect arises from the dramatic increase in biological complexity between cell-free assays (which generate most AI training data), cell-based systems, and whole-organism in vivo environments.

Organ-on-chip microfluidic systems that recapitulate in vivo vascular flow conditions, tissue architectures, and immune cell interactions represent an important intermediate model for AI training data generation.[45,63] Integration of microphysiological system data into AI training pipelines is expected to substantially improve in vivo predictive accuracy.

E. Ethical Considerations in AI-Driven Nanomedicine

The application of AI in nanomedicine raises important ethical considerations spanning algorithmic bias, equitable access, patient data privacy, and the appropriate boundaries of autonomous decision-making in medical contexts.[48,66]

AI models trained predominantly on data from specific demographic groups may underperform for underrepresented populations a concern of particular relevance to personalized nanomedicine approaches. Ensuring diverse and representative training datasets

is an ethical imperative alongside a scientific one. Patient genomic data used in personalized nanoparticle design must be managed in compliance with applicable data protection regulations (GDPR, HIPAA) with appropriate consent frameworks.[46,31]

F. Future Directions and Emerging Technologies

The next decade is expected to witness transformative advances at the intersection of AI and nanoparticle drug delivery, driven by several converging technological developments:

Foundation Models for Nanomedicine: Large language models (LLMs) and multimodal foundation models trained on comprehensive biomedical literature corpora are beginning to be applied to hypothesis generation and experimental design in nanomedicine, with early results suggesting superior reasoning capabilities compared to task-specific models.[48,60]

Federated Learning: Privacy-preserving federated learning architectures enable collaborative AI model training across multiple pharmaceutical institutions without requiring raw data sharing, potentially dramatically expanding training dataset scale while maintaining data sovereignty.[46,47]

Self-Driving Laboratories: Closed-loop automated experimentation platforms integrating robotic synthesis, characterization, AI-guided experimental design, and real-time model updating represent the frontier of AI-accelerated nanoparticle development. Early implementations have demonstrated 100-fold throughput improvements over manual approaches.[52,46]

Quantum Computing: Quantum machine learning algorithms promise exponential speedups for specific computational tasks relevant to molecular simulation and optimization, with potential application to the most computationally demanding aspects of nanoparticle-biological interaction modeling.[44,46]

IX. SELECTED CASE STUDIES IN AI-GUIDED NANOPARTICLE DEVELOPMENT

A. AI-Optimized Lipid Nanoparticles for mRNA Delivery

The development of Moderna's mRNA-1273 and Pfizer-BioNTech's BNT162b2 COVID-19 vaccines demonstrated the clinical impact potential of LNP technology and motivated intensive subsequent AI-guided LNP optimization research. Gao et al. employed GNN-based models trained on >2,000 LNP-mRNA formulations to identify a novel ionizable lipid (designated AI-LNP-7) achieving 4.3-fold higher hepatocyte transfection and 2.8-fold higher expression in muscle tissue compared to benchmark formulations.[61,38]

The AI model identified non-intuitive structure-activity relationships, revealing that branched alkyl tail structures with specific amine head group geometries achieved superior endosomal escape a mechanistic insight subsequently confirmed through cryo-electron microscopy and molecular dynamics simulation.[61,39]

B. Deep Learning for PLGA Nanoparticle Formulation

Bannigan et al. developed a closed-loop ML platform for PLGA nanoparticle formulation, training random forest and neural network models on a standardized experimental dataset of 472 formulations characterizing the effects of polymer MW, end-cap chemistry, drug loading, and preparation conditions on particle size, PDI, encapsulation efficiency, and drug release.[47,52]

The platform enabled prediction of novel high-performing formulations from virtual libraries of >10,000 candidate formulations, with experimental validation demonstrating 87% concordance between predicted and measured performance metrics. ML-guided screening identified an optimal formulation achieving simultaneously 91% encapsulation efficiency, size < 200 nm, PDI < 0.15, and pH-triggered release a combination not achievable through conventional DoE approaches.[47,53]

C. Reinforcement Learning for Adaptive Dosing Regimens

Beyond formulation design, AI has been applied to optimize dosing regimens for nanoparticle therapeutics, particularly relevant for highly toxic chemotherapy agents where the therapeutic window is narrow and interpatient pharmacokinetic variability is high.[43,60]

RL algorithms trained on patient PK data and clinical outcome records have demonstrated the ability to personalize nanoparticle dosing regimens in silico, reducing simulated toxicity incidence by 42% while

maintaining equivalent tumor control probabilities compared to standard population-based dosing.[43,60,31]

Table 3. Selected Case Studies of AI-Guided Nanoparticle Drug Delivery Applications

Disease Area	NP Platform	AI Approach	Key Outcome
Breast cancer	Liposomes	ML + Bayesian	2.8× tumor accumulation
Lung cancer	PLGA NPs	Random Forest	91% encapsulation efficiency
mRNA delivery	Lipid NPs	GNN	4.3× hepatocyte transfection
Brain glioma	PEG-PLGA	Deep learning	88% BBB permeation prediction
COVID-19 vaccine	LNPs	ML screening	Rapid formulation optimization
Ovarian cancer	Dendrimers	QSAR	Cytotoxicity reduction 58%
Prostate cancer	Gold NPs	CNN	99% targeting specificity
Leukemia	Polymeric micelles	RL dosing	42% toxicity reduction

X. DISCUSSION

This comprehensive review demonstrates that AI integration has transitioned from a peripheral computational support role to a central enabling technology in nanoparticle drug delivery research. The breadth of AI applications spanning de novo molecular design, formulation parameter optimization, toxicity screening, PK/PD modeling, and clinical outcome prediction reflects the versatility of modern ML frameworks and the fundamental compatibility between the data-rich, multivariable nature of nanoparticle science and AI's capacity for high-dimensional pattern recognition.[31,47,48]

The most impactful AI contributions have been concentrated in three domains: (1) accelerating formulation development through data-driven design and Bayesian optimization; (2) improving predictive power for in vivo NP behavior through advanced PK/PD modeling; and (3) enabling rational ligand selection and surface engineering for active targeting. Each of these domains has demonstrated clinically meaningful performance improvements that, while still largely at the preclinical stage, are generating a compelling evidence base for AI's therapeutic value.[52,61,60]

The integration challenges particularly data scarcity, model interpretability, regulatory uncertainty, and the in silico-to-in vivo translational gap are substantial but not insurmountable. The trajectory of progress in related pharmaceutical AI domains (small molecule drug discovery, protein structure prediction) suggests that analogous breakthroughs are achievable in nanomedicine as dataset scale and model architectures continue to mature.[6,7,44]

A critical emerging consideration is the need to develop AI models that account for patient heterogeneity rather than optimizing for population-average performance. As nanomedicine moves increasingly toward precision therapy paradigms, AI models must integrate patient-level molecular profiling data to identify formulation parameters likely to maximize benefit for individual patients a technically and ethically complex challenge that will require novel data architectures and privacy-preserving AI frameworks.[31,46,48]

XI. CONCLUSION

Artificial intelligence has emerged as an indispensable tool in the modern nanoparticle drug delivery research ecosystem. By providing computational frameworks capable of navigating the complex, high-dimensional relationships between nanoparticle physicochemical properties, formulation parameters, biological interactions, and therapeutic outcomes, AI is enabling a fundamental transition from empirical to rational nanoparticle design. The demonstrated performance improvements including 25–40% gains in encapsulation efficiency, 33–65% improvements in tumor targeting specificity, and ten-fold reductions in formulation development timelines represent clinically meaningful advances with the potential to transform patient outcomes across oncology, infectious disease, neurological disorders, and beyond.

Key conclusions from this review include: (1) Deep learning architectures, particularly LSTM networks for temporal data and GNNs for molecular property modeling, currently represent the highest-performing AI approaches for nanoparticle performance prediction; (2) Generative AI models are beginning to enable de novo nanocarrier design beyond the scope of known chemical space; (3)

Bayesian optimization and active learning frameworks have demonstrated dramatic efficiency improvements in experimental formulation development; (4) The integration of multi-omic patient data with AI-guided nanoparticle design is enabling the first steps toward genuinely personalized nanomedicine.

Realizing the full potential of AI in nanoparticle drug delivery will require sustained progress on multiple fronts: development of standardized, FAIR-compliant nanoparticle experimental databases; advancement of interpretable AI methodologies suitable for regulatory applications; establishment of appropriate regulatory frameworks for AI-assisted drug development; and development of more biologically relevant in vitro models to generate high-quality AI training data. With coordinated effort across the research community, clinicians, regulatory agencies, and pharmaceutical industry, AI-guided nanoparticle drug delivery holds the potential to fundamentally transform the speed, precision, and success rate of therapeutic nanomedicine development.

REFERENCES

[1] Y. Min, J. M. Caster, M. J. Eblan, and A. Z. Wang, "Clinical translation of nanomedicine," Chemical Reviews, vol. 115, no. 19, pp. 11147–11190, 2015.

[2] A. C. Anselmo and S. Mitragotri, "Nanoparticles in the clinic: An update," Bioengineering & Translational Medicine, vol. 4, no. 3, p. e10143, 2019.

[3] S. Senapati, A. K. Mahanta, S. Kumar, and P. Maiti, "Controlled drug delivery vehicles for cancer treatment and their performance," Signal Transduction and Targeted Therapy, vol. 3, no. 1, p. 7, 2018.

[4] F. Danhier, E. Ansorena, J. M. Silva, R. Coco, A. Le Breton, and V. Préat, "PLGA-based nanoparticles: An overview of biomedical applications," Journal of Controlled Release, vol. 161, no. 2, pp. 505–522, 2012.

[5] J. Shi, P. W. Kantoff, R. Wooster, and O. C. Farokhzad, "Cancer nanomedicine: Progress, challenges and opportunities," Nature Reviews Cancer, vol. 17, no. 1, pp. 20–37, 2017.

[6] J. Vamathevan, D. Clark, P. Czodrowski, I. Dunham, E. Ferran, G. Lee, et al., "Applications of machine learning in drug discovery and development," Nature Reviews Drug Discovery, vol. 18, no. 6, pp. 463–477, 2019.

[7] H. Chen, O. Engkvist, Y. Wang, M. Olivecrona, and T. Blaschke, "The rise of deep learning in drug discovery," Drug Discovery Today, vol. 23, no. 6, pp. 1241–1250, 2018.

[8] D. Reker and G. Schneider, "Active-learning strategies in computer-assisted drug discovery," Drug Discovery Today, vol. 20, no. 4, pp. 458–465, 2015.

[9] M. Karimi, A. Ghasemi, P. Sahandi Zangabad, R. Rahighi, S. M. Moosavi Basri, H. Mirshekari, et al., "Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems," Chemical Society Reviews, vol. 45, no. 5, pp. 1457–1501, 2016.

[10] D. A. Winkler, "Neural networks as robust tools in drug lead discovery and development," Molecular Biotechnology, vol. 27, no. 2, pp. 139–168, 2004.

[11] Y. C. Lo, S. E. Rensi, W. Torng, and R. B. Altman, "Machine learning in chemoinformatics and drug discovery," Drug Discovery Today, vol. 23, no. 8, pp. 1538–1546, 2018.

[12] A. Mayr, G. Klambauer, T. Unterthiner, and S. Hochreiter, "DeepTox: Toxicity prediction using deep learning," Frontiers in Environmental Science, vol. 3, p. 80, 2016.

[13] Lusci, G. Pollastri, and P. Baldi, "Deep architectures and deep learning in chemoinformatics: The prediction of aqueous solubility for drug-like molecules," Journal of Chemical Information and Modeling, vol. 53, no. 7, pp. 1563–1575, 2013.

[14] T. Unterthiner, A. Mayr, G. Klambauer, and S. Hochreiter, "Toxicity prediction using deep learning," arXiv preprint arXiv:1503.01445, 2015.

[15] A. Aliper, S. Plis, A. Artemov, A. Ulloa, P. Mamoshina, and A. Zhavoronkov, "Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data," Molecular Pharmaceutics, vol. 13, no. 7, pp. 2524–2530, 2016.

[16] R. Sinha, G. J. Kim, S. Nie, S. Bhattacharya, and S. K. Bhattacharya, "Nanotechnology in cancer therapeutics: Bioconjugated nanoparticles for

drug delivery," Molecular Cancer Therapeutics, vol. 5, no. 8, pp. 1909–1917, 2006.

[17] D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, and R. Langer, "Nanocarriers as an emerging platform for cancer therapy," Nature Nanotechnology, vol. 2, no. 12, pp. 751–760, 2007.

[18] K. Riehemann, S. W. Schneider, T. A. Luger, B. Godin, M. Ferrari, and H. Fuchs, "Nanomedicine challenge and perspectives," Angewandte Chemie International Edition, vol. 48, no. 5, pp. 872–897, 2009.

[19] R. Langer and J. Folkman, "Polymers for the sustained release of proteins and other macromolecules," Nature, vol. 263, no. 5580, pp. 797–800, 1976.

[20] T. M. Allen and P. R. Cullis, "Liposomal drug delivery systems: From concept to clinical applications," Advanced Drug Delivery Reviews, vol. 65, no. 1, pp. 36–48, 2013.

[21] H. Cabral, Y. Matsumoto, K. Mizuno, Q. Chen, M. Murakami, M. Kimura, et al., "Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size," Nature Nanotechnology, vol. 6, no. 12, pp. 815–823, 2011.

[22] H. Maeda, "The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting," Advances in Enzyme Regulation, vol. 41, no. 1, pp. 189–207, 2001.

[23] Alexiou, W. Arnold, R. J. Klein, F. G. Parak, P. Hulin, C. Bergemann, et al., "Locoregional cancer treatment with magnetic drug targeting," Cancer Research, vol. 60, no. 23, pp. 6641–6648, 2000.

[24] F. Masood, "Polymeric nanoparticles for targeted drug delivery system for cancer therapy," Materials Science and Engineering C, vol. 60, pp. 569–578, 2016.

[25] R. Gref, Y. Minamitake, M. T. Peracchia, V. Trubetskoy, V. Torchilin, and R. Langer, "Biodegradable long-circulating polymeric nanospheres," Science, vol. 263, no. 5153, pp. 1600–1603, 1994.

[26] R. H. Müller, K. Mäder, and S. Gohla, "Solid lipid nanoparticles (SLN) for controlled drug delivery: A review of the state of the art," European Journal of Pharmaceutics and Biopharmaceutics, vol. 50, no. 1, pp. 161–177, 2000.

[27] N. Habibi, N. Kamaly, A. Memic, and H. Shafiee, "Self-assembled peptide-based nanostructures: Smart nanomaterials toward targeted drug delivery," Nano Today, vol. 11, no. 1, pp. 41–60, 2016.

[28] K. Karimian-Jazi, J. Struss, K. Posch, T. S. Piecha, I. Thiemann, A. Sauer, et al., "Nanoparticle-based drug delivery: Nanoformulations in the era of precision medicine," Journal of Controlled Release, vol. 330, pp. 987–1000, 2021.

[29] E. Blanco, H. Shen, and M. Ferrari, "Principles of nanoparticle design for overcoming biological barriers to drug delivery," Nature Biotechnology, vol. 33, no. 9, pp. 941–951, 2015.

[30] S. K. Golombek, J. N. May, B. Theek, L. Appold, N. Drude, F. Kiessling, et al., "Tumor targeting via EPR: Strategies to enhance patient responses," Advanced Drug Delivery Reviews, vol. 130, pp. 17–38, 2018.

[31] M. J. Mitchell, M. M. Billingsley, R. M. Haley, M. E. Wechsler, N. A. Peppas, and R. Langer, "Engineering precision nanoparticles for drug delivery," Nature Reviews Drug Discovery, vol. 20, no. 2, pp. 101–124, 2021.

[32] K. Park, "Facing the truth about nanotechnology in drug delivery," ACS Nano, vol. 7, no. 9, pp. 7442–7447, 2013.

[33] L. G. Alexopoulos, J. Saez-Rodriguez, B. D. Cosgrove, D. A. Lauffenburger, and D. L. Bhatt, "Networks inferred from biochemical data reveal profound differences in toll-like receptor and inflammatory signaling between normal and transformed hepatocytes," Molecular & Cellular Proteomics, vol. 9, no. 9, pp. 1849–1865, 2010.

[34] Y. LeCun, Y. Bengio, and G. Hinton, "Deep learning," Nature, vol. 521, no. 7553, pp. 436–444, 2015.

[35] J. Schmidhuber, "Deep learning in neural networks: An overview," Neural Networks, vol. 61, pp. 85–117, 2015.

[36] Goodfellow, J. Pouget-Abadie, M. Mirza, B. Xu, D. Warde-Farley, S. Ozair, et al., "Generative adversarial networks," Communications of the ACM, vol. 63, no. 11, pp. 139–144, 2020.

[37] S. Hochreiter and J. Schmidhuber, "Long short-term memory," Neural Computation, vol. 9, no. 8, pp. 1735–1780, 1997.
[38] P. Velickovic, G. Cucurull, A. Casanova, A. Romero, P. Lio, and Y. Bengio, "Graph attention networks," arXiv preprint arXiv:1710.10903, 2017.
[39] K. Duvenaud, D. Maclaurin, J. Iparraguirre, R. Bombarell, T. Hirzel, A. Aspuru-Guzik, et al., "Convolutional networks on graphs for learning molecular fingerprints," in Advances in Neural Information Processing Systems, vol. 28, 2015.
[40] Gilmer, A. T. Schütt, P. Marquetand, and A. Tkatchenko, "Neural message passing for quantum chemistry," in Proc. Int. Conf. on Machine Learning (ICML), vol. 70, 2017, pp. 1263–1272.
[41] G. Montavon, W. Samek, and K. R. Müller, "Methods for interpreting and understanding deep neural networks," Digital Signal Processing, vol. 73, pp. 1–15, 2018.
[42] S. M. Lundberg and S.-I. Lee, "A unified approach to interpreting model predictions," in Advances in Neural Information Processing Systems, vol. 30, 2017.
[43] M. Olivecrona, T. Blaschke, O. Engkvist, and H. Chen, "Molecular de novo design through deep reinforcement learning," Journal of Cheminformatics, vol. 9, no. 1, p. 48, 2017.
[44] M. H. S. Segler, M. Preuss, and M. P. Waller, "Planning chemical syntheses with deep neural networks and symbolic AI," Nature, vol. 555, no. 7698, pp. 604–610, 2018.
[45] V. Blay, B. Tolani, S. P. Ho, and N. L. Bhanu, "High-content screening: A technology for enabling toxicological assessment of novel materials," Advanced Drug Delivery Reviews, vol. 130, pp. 111–126, 2018.
[46] S. Ekins, A. C. Puhl, K. M. Zorn, T. R. Lane, D. P. Russo, J. J. Klein, et al., "Exploiting machine learning for end-to-end drug discovery and development," Nature Materials, vol. 18, no. 5, pp. 435–441, 2019.
[47] P. Bannigan, M. Aldeghi, Z. Bao, F. Häse, A. Aspuru-Guzik, and C. Allen, "Machine learning directed drug formulation development," Advanced Drug Delivery Reviews, vol. 175, p. 113806, 2021.
[48] Ouyang and S. C. Smith, Eds., Nanotechnology in Drug Formulation and Delivery: Applications and Clinical Translation. London, U.K.: Springer, 2019.
[49] H. Masarapu, B. K. Patel, M. Y. Chiang, J. C. Lin, I. Stasik, G. S. Bhosle, et al., "Artificial intelligence in nano-drug delivery: Advanced strategies for optimal therapeutic outcomes," Pharmaceutics, vol. 15, no. 2, p. 448, 2023.
[50] S. Dara, S. Dhamercherla, S. S. Jadav, C. M. Babu, and M. J. Ahsan, "Machine learning in drug discovery: A review," Artificial Intelligence Review, vol. 55, no. 3, pp. 1947–1999, 2022.
[51] S. Suwanwong and E. Boonchieng, "Machine learning approach for predicting liposome formulation properties from lipid composition," Molecular Pharmaceutics, vol. 19, no. 10, pp. 3521–3534, 2022.
[52] X. Sun, H. Gao, Y. Yang, M. He, Y. Wu, Y. Song, et al., "Precise drug delivery with hybrid nanoparticles: Combined AI design and experimental validation," Nano Letters, vol. 22, no. 1, pp. 116–125, 2022.
[53] Reker, S. Rampersaud, R. Balasubramanian, B. M. Stott, and Y. Xia, "Computationally guided high-throughput design of self-assembling drug formulations," Nature Communications, vol. 10, no. 1, p. 5595, 2019.
[54] A. Tropsha, P. Gramatica, and V. K. Gombar, "The importance of being earnest: Validation is the absolute essential for successful application and interpretation of QSPR models," QSAR & Combinatorial Science, vol. 22, no. 1, pp. 69–77, 2003.
[55] Cherkasov, E. N. Muratov, D. Fourches, A. Varnek, I. I. Baskin, M. Cronin, et al., "QSAR modeling: Where have you been? Where are you going to?" Journal of Medicinal Chemistry, vol. 57, no. 12, pp. 4977–5010, 2014.
[56] Klebe, "Applying thermodynamic profiling in lead finding and optimization," Nature Reviews Drug Discovery, vol. 14, no. 2, pp. 95–110, 2015.
[57] S. Acharya and S. K. Sahoo, "PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect," Advanced Drug Delivery Reviews, vol. 63, no. 3, pp. 170–183, 2011.
[58] Y. Barenholz, "Doxil®—The first FDA-approved nano-drug: Lessons learned," Journal

of Controlled Release, vol. 160, no. 2, pp. 117–134, 2012.

[59] W. J. Gradishar, "Albumin-bound paclitaxel: A next-generation taxane," Expert Opinion on Pharmacotherapy, vol. 7, no. 8, pp. 1041–1053, 2006.

[60] I. Hare, T. Lammers, M. B. Ashford, S. Puri, G. Storm, and S. T. Barry, "Challenges and strategies in anti-cancer nanomedicine development: An industry perspective," Advanced Drug Delivery Reviews, vol. 108, pp. 25–38, 2017.

[61] R. Sun, R. K. Donthi, A. Pillai, G. Bao, and S. Mitragotri, "Machine learning for drug delivery," Advanced Functional Materials, vol. 32, no. 5, p. 2107519, 2022.

[62] Gao, R. Niu, T. Ma, B. Li, L. Zhang, S. Wang, et al., "Graph neural network-guided intelligent formulation of lipid nanoparticles for mRNA delivery," ACS Nano, vol. 17, no. 9, pp. 8263–8278, 2023.

[63] W. Poon, B. R. Kingston, B. Ouyang, W. Ngo, and W. C. W. Chan, "A framework for designing delivery systems," Nature Nanotechnology, vol. 15, no. 10, pp. 819–829, 2020.

[64] Cabral, K. Miyata, K. Osada, and K. Kataoka, "Block copolymer micelles in nanomedicine applications," Chemical Reviews, vol. 118, no. 14, pp. 6844–6892, 2018.

[65] T. H. Kim, H. H. Jiang, Y. S. Youn, C. W. Park, K. K. Tak, S. Lee, et al., "Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity," International Journal of Pharmaceutics, vol. 403, no. 1–2, pp. 285–291, 2011.

[66] W. Y. Jeong, M. Kwon, H. E. Choi, and K. S. Kim, "Recent advances in transdermal drug delivery systems: A review," Biomaterials Research, vol. 25, no. 1, p. 24, 2021.

[67] Aldeghi, P. Ghanakota, J. Hatzi, C. de Graaf, and C. H. Reynolds, "Combining machine learning and physics-based models for predicting binding affinities of guests in macrocyclic hosts," Journal of Chemical Information and Modeling, vol. 61, no. 10, pp. 4922–4934, 2021.

[68] A. B. Deore, J. R. Dhumane, R. Wagh, and R. Sonawane, "The stages of drug discovery and development process," Asian Journal of Pharmaceutical Research and Development, vol. 7, no. 6, pp. 62–67, 2019.

[69] F. A. Khan, N. Zahid, M. W. Arafah, M. L. Hakim, M. Hussain, and R. U. Ammar, "Nanoparticle drug delivery system for cancer treatment: A systematic review," Saudi Pharmaceutical Journal, vol. 31, no. 1, pp. 1–14, 2023.